Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patientswith high-risk rhabdomyosarcoma: A report from the children's oncology group

Brenda J. Weigel, Elizabeth Lyden, James R. Anderson, William H. Meyer, David M. Parham, David A. Rodeberg, Jeff M. Michalski, Douglas S. Hawkins, Carola A.S. Arndt

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Purpose Patients with metastatic rhabdomyosarcoma (RMS), except those younger than 10 years with embryonal RMS, have an estimated long-term event-free survival (EFS) of less than 20%. The main goal of this study was to improve outcome of patients with metastatic RMS by dose intensification with interval compression, use of the most active agents determined in phase II window studies, and use of irinotecan as a radiation sensitizer. Patients and Methods Patients with metastatic RMS received 54 weeks of therapy: blocks of therapy with vincristine/ irinotecan (weeks 1 to 6, 20 to 25, and 47 to 52), interval compression with vincristine/doxorubicin/ cyclophosphamide alternating with etoposide/ifosfamide (weeks 7 to 19 and 26 to 34), and vincristine/dactinomycin/cyclophosphamide (weeks 38 to 46). Radiation therapy occurred at weeks 20 to 25 (primary) but was also permitted at weeks 1 to 6 (for intracranial or paraspinal extension) and weeks 47 to 52 (for extensive metastatic sites). Results One hundred nine eligible patients were enrolled, with a median follow-up of surviving patients of 3.8 years (3-year EFS for all patients, 38% [95% CI, 29% to 48%]; survival, 56% [95% CI, 46% to 66%]). Patients with one or no Oberlin risk factor (age . 10 years or , 1 year, unfavorable primary site of disease, three metastatic sites, and bone or bone marrow involvement) had a 3-year EFS of 69% (95% CI, 52% to 82%); high-risk patients with two or more risk factors had a 3-year EFS of 20% (95% CI, 11% to 30%). Toxicity was similar to that on prior RMS studies. Conclusion Patients with metastatic RMS with one or no Oberlin risk factor had an improved 3-year EFS of 69% on ARST0431 compared with an historical cohort frompooled European and US studies; those with two or more risk factors have a dismal prognosis, and new approaches are needed for this very-high-risk group.

Original languageEnglish (US)
Pages (from-to)117-122
Number of pages6
JournalJournal of Clinical Oncology
Volume34
Issue number2
DOIs
StatePublished - Jan 10 2016

Fingerprint

irinotecan
Ifosfamide
Rhabdomyosarcoma
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Radiation
Disease-Free Survival
Therapeutics
Embryonal Rhabdomyosarcoma
Radiation-Sensitizing Agents

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patientswith high-risk rhabdomyosarcoma : A report from the children's oncology group. / Weigel, Brenda J.; Lyden, Elizabeth; Anderson, James R.; Meyer, William H.; Parham, David M.; Rodeberg, David A.; Michalski, Jeff M.; Hawkins, Douglas S.; Arndt, Carola A.S.

In: Journal of Clinical Oncology, Vol. 34, No. 2, 10.01.2016, p. 117-122.

Research output: Contribution to journalArticle

Weigel, Brenda J. ; Lyden, Elizabeth ; Anderson, James R. ; Meyer, William H. ; Parham, David M. ; Rodeberg, David A. ; Michalski, Jeff M. ; Hawkins, Douglas S. ; Arndt, Carola A.S. / Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patientswith high-risk rhabdomyosarcoma : A report from the children's oncology group. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 2. pp. 117-122.
@article{9dd406e0c396463d94fcdc0cf2865a48,
title = "Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patientswith high-risk rhabdomyosarcoma: A report from the children's oncology group",
abstract = "Purpose Patients with metastatic rhabdomyosarcoma (RMS), except those younger than 10 years with embryonal RMS, have an estimated long-term event-free survival (EFS) of less than 20{\%}. The main goal of this study was to improve outcome of patients with metastatic RMS by dose intensification with interval compression, use of the most active agents determined in phase II window studies, and use of irinotecan as a radiation sensitizer. Patients and Methods Patients with metastatic RMS received 54 weeks of therapy: blocks of therapy with vincristine/ irinotecan (weeks 1 to 6, 20 to 25, and 47 to 52), interval compression with vincristine/doxorubicin/ cyclophosphamide alternating with etoposide/ifosfamide (weeks 7 to 19 and 26 to 34), and vincristine/dactinomycin/cyclophosphamide (weeks 38 to 46). Radiation therapy occurred at weeks 20 to 25 (primary) but was also permitted at weeks 1 to 6 (for intracranial or paraspinal extension) and weeks 47 to 52 (for extensive metastatic sites). Results One hundred nine eligible patients were enrolled, with a median follow-up of surviving patients of 3.8 years (3-year EFS for all patients, 38{\%} [95{\%} CI, 29{\%} to 48{\%}]; survival, 56{\%} [95{\%} CI, 46{\%} to 66{\%}]). Patients with one or no Oberlin risk factor (age . 10 years or , 1 year, unfavorable primary site of disease, three metastatic sites, and bone or bone marrow involvement) had a 3-year EFS of 69{\%} (95{\%} CI, 52{\%} to 82{\%}); high-risk patients with two or more risk factors had a 3-year EFS of 20{\%} (95{\%} CI, 11{\%} to 30{\%}). Toxicity was similar to that on prior RMS studies. Conclusion Patients with metastatic RMS with one or no Oberlin risk factor had an improved 3-year EFS of 69{\%} on ARST0431 compared with an historical cohort frompooled European and US studies; those with two or more risk factors have a dismal prognosis, and new approaches are needed for this very-high-risk group.",
author = "Weigel, {Brenda J.} and Elizabeth Lyden and Anderson, {James R.} and Meyer, {William H.} and Parham, {David M.} and Rodeberg, {David A.} and Michalski, {Jeff M.} and Hawkins, {Douglas S.} and Arndt, {Carola A.S.}",
year = "2016",
month = "1",
day = "10",
doi = "10.1200/JCO.2015.63.4048",
language = "English (US)",
volume = "34",
pages = "117--122",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patientswith high-risk rhabdomyosarcoma

T2 - A report from the children's oncology group

AU - Weigel, Brenda J.

AU - Lyden, Elizabeth

AU - Anderson, James R.

AU - Meyer, William H.

AU - Parham, David M.

AU - Rodeberg, David A.

AU - Michalski, Jeff M.

AU - Hawkins, Douglas S.

AU - Arndt, Carola A.S.

PY - 2016/1/10

Y1 - 2016/1/10

N2 - Purpose Patients with metastatic rhabdomyosarcoma (RMS), except those younger than 10 years with embryonal RMS, have an estimated long-term event-free survival (EFS) of less than 20%. The main goal of this study was to improve outcome of patients with metastatic RMS by dose intensification with interval compression, use of the most active agents determined in phase II window studies, and use of irinotecan as a radiation sensitizer. Patients and Methods Patients with metastatic RMS received 54 weeks of therapy: blocks of therapy with vincristine/ irinotecan (weeks 1 to 6, 20 to 25, and 47 to 52), interval compression with vincristine/doxorubicin/ cyclophosphamide alternating with etoposide/ifosfamide (weeks 7 to 19 and 26 to 34), and vincristine/dactinomycin/cyclophosphamide (weeks 38 to 46). Radiation therapy occurred at weeks 20 to 25 (primary) but was also permitted at weeks 1 to 6 (for intracranial or paraspinal extension) and weeks 47 to 52 (for extensive metastatic sites). Results One hundred nine eligible patients were enrolled, with a median follow-up of surviving patients of 3.8 years (3-year EFS for all patients, 38% [95% CI, 29% to 48%]; survival, 56% [95% CI, 46% to 66%]). Patients with one or no Oberlin risk factor (age . 10 years or , 1 year, unfavorable primary site of disease, three metastatic sites, and bone or bone marrow involvement) had a 3-year EFS of 69% (95% CI, 52% to 82%); high-risk patients with two or more risk factors had a 3-year EFS of 20% (95% CI, 11% to 30%). Toxicity was similar to that on prior RMS studies. Conclusion Patients with metastatic RMS with one or no Oberlin risk factor had an improved 3-year EFS of 69% on ARST0431 compared with an historical cohort frompooled European and US studies; those with two or more risk factors have a dismal prognosis, and new approaches are needed for this very-high-risk group.

AB - Purpose Patients with metastatic rhabdomyosarcoma (RMS), except those younger than 10 years with embryonal RMS, have an estimated long-term event-free survival (EFS) of less than 20%. The main goal of this study was to improve outcome of patients with metastatic RMS by dose intensification with interval compression, use of the most active agents determined in phase II window studies, and use of irinotecan as a radiation sensitizer. Patients and Methods Patients with metastatic RMS received 54 weeks of therapy: blocks of therapy with vincristine/ irinotecan (weeks 1 to 6, 20 to 25, and 47 to 52), interval compression with vincristine/doxorubicin/ cyclophosphamide alternating with etoposide/ifosfamide (weeks 7 to 19 and 26 to 34), and vincristine/dactinomycin/cyclophosphamide (weeks 38 to 46). Radiation therapy occurred at weeks 20 to 25 (primary) but was also permitted at weeks 1 to 6 (for intracranial or paraspinal extension) and weeks 47 to 52 (for extensive metastatic sites). Results One hundred nine eligible patients were enrolled, with a median follow-up of surviving patients of 3.8 years (3-year EFS for all patients, 38% [95% CI, 29% to 48%]; survival, 56% [95% CI, 46% to 66%]). Patients with one or no Oberlin risk factor (age . 10 years or , 1 year, unfavorable primary site of disease, three metastatic sites, and bone or bone marrow involvement) had a 3-year EFS of 69% (95% CI, 52% to 82%); high-risk patients with two or more risk factors had a 3-year EFS of 20% (95% CI, 11% to 30%). Toxicity was similar to that on prior RMS studies. Conclusion Patients with metastatic RMS with one or no Oberlin risk factor had an improved 3-year EFS of 69% on ARST0431 compared with an historical cohort frompooled European and US studies; those with two or more risk factors have a dismal prognosis, and new approaches are needed for this very-high-risk group.

UR - http://www.scopus.com/inward/record.url?scp=84954307137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954307137&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.63.4048

DO - 10.1200/JCO.2015.63.4048

M3 - Article

C2 - 26503200

AN - SCOPUS:84954307137

VL - 34

SP - 117

EP - 122

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -